Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417741 | PMC |
| http://dx.doi.org/10.2450/2012.0142-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost-utility analysis.
Vox Sang
December 2024
Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands.
Background And Objectives: Foetal and neonatal alloimmune thrombocytopenia (FNAIT) results from maternal platelet-directed antibodies and can result in severe intracranial haemorrhage (ICH) in foetuses and newborns. Screening for human platelet antigen-1a (HPA-1a)-directed antibodies during pregnancy could allow timely intervention with antenatal treatment and prevent ICH. We assessed the cost effectiveness of HPA-1a typing and anti-HPA-1a-screening as part of the prenatal screening programme.
View Article and Find Full Text PDFEvidence that CD36 is expressed on red blood cells and constitutes a novel blood group system of clinical importance.
Vox Sang
May 2024
Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Background And Objectives: Polymorphic molecules expressed on the surface of certain blood cells are traditionally categorized as blood groups and human platelet or neutrophil antigens. CD36 is widely considered a platelet antigen (Nak) and anti-CD36 can cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) in CD36-negative pregnant women. CD36 is used as a marker of differentiation in early erythroid culture.
View Article and Find Full Text PDFAn optimized procedure for Luminex-based human platelet antigen-specific antibody screening and identification (PakLx assay) with a cost-effective approach and improved sensitivity.
Vox Sang
December 2023
HLA-HPA Laboratory, EFS Blood Center of Brittany, Rennes, France.
Background And Objectives: Detection of anti-platelet antibodies is required for the diagnosis of foetal/neonatal alloimmune thrombocytopaenia. The most commonly used methods for anti-platelet antibody detection are the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and the Luminex bead assay (PakLx). However, for economic reasons, the use of the PakLx assay is limited.
View Article and Find Full Text PDFA first WHO reference reagent for the detection of anti-human platelet antigen-15b.
Vox Sang
February 2022
Biotherapeutics Division, National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK.
Background And Objectives: Alloantibodies to human platelet antigen-15b (anti-HPA-15b) have been detected in mothers with foetal-neonatal alloimmune thrombocytopenia and in multiply transfused patients. Assays used to detect this antibody, which aids in disease diagnosis, can be unreliable and vary in sensitivity. The objective was to generate a stable, lyophilized anti-HPA-15b preparation and evaluate its suitability as a World Health Organization (WHO) reference reagent for use in the quality control of platelet alloantibody detection assays.
View Article and Find Full Text PDFReport on the 19th International Society of Blood Transfusion Platelet Immunology Workshop 2018.
Vox Sang
November 2020
Medical Affairs and Innovation, Héma-Québec, Saint-Laurent, QC, Canada.
Background And Objectives: The aims of the 19th International Society of Blood Transfusion Platelet Immunology Workshop were to compare the sensitivity and specificity of in-house and commercially available methods for the detection of alloantibodies against human platelet antigens. Survey regarding laboratory management of samples collected for the diagnosis of foetal neonatal alloimmune thrombocytopenia was also conducted.
Materials And Methods: Twenty-nine laboratories from 17 countries were invited to participate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!